Pioneer Clinical Trials A study is underway in the United States to check the effectiveness of nasal vaccines in the treatment of Alzheimer’s disease.
The study will be conducted at Brigham and Women’s Hospital in Boston. Participants will be recruited this week. The first human trial A nasal vaccine against this disease.
“If human clinical trials show that the vaccine is safe and effective, this may represent a non-toxic treatment for patients with Alzheimer’s disease, and it can also be given early to help prevent Alzheimer’s disease in high-risk groups,” Howardway Dr. Na said. The director of the An Romney Center for Neurological Diseases at Brigham University will lead the research, Said in a statement.
The vaccine will test an immunotherapy drug called Protollin, which works by stimulating the body’s immune system to target beta amyloid plaques that accumulate in the brain. Scientists believe that these accumulations are one of the ways that human brain cells can’t work properly in Alzheimer’s disease.
According to a Hospital press release, The first phase of the trial will involve 16 participants between the ages of 60 and 85, who have early symptomatic Alzheimer’s disease but are otherwise healthy. They will each receive two doses of Protollin, one week apart.
It has been found that Protollin is safe in other vaccines, Weiner told the Boston Herald that his pre-trial studies showed that the nasal dose Provide the best results, And did not find any major side effects.
Global research involving London, Ontario.Researchers investigate changes in heart valve surgery
Weiner told the Herald that the vaccine “can help treat this disease, and more importantly, it can Give to people at risk of illness Or have it without knowing it. “
He said that despite normal cognition, many people in their 50s and 60s show signs of Alzheimer’s in brain imaging.
According to the hospital’s statement, the test will be used to determine the “safety and tolerability of the vaccine.” Researchers will also track the impact of the vaccine on participants’ immune responses by measuring white blood cell counts.
The first phase of the trial will last approximately six months, and then a second trial of 150 people will begin for a year.
Alzheimer’s disease is a type of dementia that worsens a person’s memory, thinking, and behavior. Eventually, these cognitive symptoms become severe enough to interfere with daily work. It is the most common cause of dementia, accounting for 60% to 80% of all dementia cases.
The Alzheimer’s Association estimates that more than 747,000 Canadians have Living with Alzheimer’s Or other forms of dementia.
According to data from the National Institute on Aging (NIA), scientists Unable to determine the exact cause Alzheimer’s disease, but it is believed that it may include a combination of genetic, environmental, and lifestyle factors.
© 2021 Global News, a division of Corus Entertainment Inc.
